N. Geyvandova

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

M. Buti, M. Biermer, T. Asselah, 2023, The Lancet Gastroenterology & Hepatology.

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.

W. Haefeli, M. Haag, U. Merle, 2022, The Lancet. Infectious diseases.

Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study

S. Zeuzem, P. Lampertico, H. Wedemeyer, 2023, 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber.

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.

A. Berger, S. Ciesek, P. Lampertico, 2023, The New England journal of medicine.

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

S. Zeuzem, P. Lampertico, H. Wedemeyer, 2022, Journal of Hepatology.